Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2010 TOWARd trial of total neoadjuvant therapy and watch-and-wait for low rectal cancer
jRCTs031220288Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Clinical complete response rate at final response evaluation and Overall survival. Started Sep 2022; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs031220288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220288.